Previous 10 | Next 10 |
Options exercised on two targets; Voyager eligible to receive associated development, regulatory, and commercial milestones, plus tiered royalties With option exercise, potential to expand agreement to include capsids for up to two additional targets extends for next 18 months CAM...
2023-03-06 03:11:42 ET Summary In Q4 2022, the company's revenue was $24.29 billion, up 1.9% from the last three months of 2021, despite a significant decrease in people's desire to vaccinate against COVID-19. According to the Wall Street Journal, Pfizer's management is in talks t...
2023-03-04 13:45:00 ET A record $138B was invested by the 15 largest pharmaceutical companies in 2022, a staggering 43% increase since 2017, according to an IQVIA report. That $138B accounted for ~19% of these companies' overall sales. IQVIA also found that although biopharma in...
Novartis ( NYSE: NVS ) completed a filing to the U.S. FDA seeking approval of a Millburn, N.J.-based radioligand therapy manufacturing facility for commercial production of prostate cancer drug Pluvicto for U.S. patients. The Swiss pharma giant added that it has requested an expedited...
Gossamer Bio ( NASDAQ: GOSS ) lost ~6% Wednesday after Guggenheim initiated its coverage with a Neutral rating, citing a challenging commercial outlook for the company's tyrosine kinase inhibitor (TKI) seralutinib targeted at pulmonary arterial hypertension (PAH). While noting tha...
FBI Director Christopher Wray said that the agency believes that the novel coronavirus which causes COVID-19 likely originated from a lab leak in Wuhan, China. "The FBI has for quite some time now assessed that the origins of the pandemic are most likely a potential lab incident in Wuhan," Wr...
Summary Alnylam's fourth quarter results were consistent with recently updated guidance, while guidance for FY'23 was modestly weaker for product revenue and more significantly weaker for collaboration revenue. The FDA will conduct an advisory panel meeting for the company's application...
Celldex Therapeutics ( NASDAQ: CLDX ) added ~12% marking the biggest intraday gain since November after the biotech announced early-stage results for its experimental monoclonal antibody barzolvolimab from patients with the skin condition urticaria. Citing data from a Phase 1b tri...
Summary With the dollar still strong and inflation fears still looming, now is an especially good time for US investors to buy more foreign dividend stocks. US investors should also consider tax advantages of splitting international dividend stock exposure between taxable and tax-shelte...
Summary Chengdu Keymed Bio and Lepu Biopharma out-licensed global rights for their partnered Claudin 18.2 antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront and up to $1.1 billion in milestones. The $937 million agreement between Beijing InnoCare and Biog...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...